mAbxience | News
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals market
08/01/2022
A further milestone for Fresenius Kabi’s Vision 2026 growth strategy as the company invests on the core growth vector “Broaden in Biopharma” The combination of both companies positions Fresenius Kabi for accelerated medium- and long-term growth building on a highly complementary product offering in one of the fastest-growing areas of healthcare Enables entry into high-growth […]
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience
04/19/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin®. The product will be marketed under the proprietary name ALYMSYS® and represents the third bevacizumab biosimilar approved in the U.S. ALYMSYS® was developed […]
Insud Pharma and Fresenius Kabi combine efforts to accelerate the growth of mAbxience
03/31/2022
This agreement will bring new business to the biotech company, which is expanding its manufacturing capabilities and maintains its identity, brand, and complete team The transaction validates mAbxience differentiated core competencies in the development, manufacturing and commercialization of biopharmaceutical products With this strategic transaction the Spanish group Insud will also have resources to […]
Cipla enters partnership to provide affordable oncology biosimilars to South Africa
03/30/2022
Cipla Medpro and the wholly owned subsidiary of Cipla Limited, India have finalised a partnership agreement with the global biotechnology company mAbxience, to get oncology and respiratory-related biosimilars to South Africa. These medicine products for the treatment of cancer are on the WHO Model List of Essential Medicines. The mAbxience partnership will enable Cipla to […]
Insud Pharma donation and assistance – Ukraine war situation
03/07/2022
At Insud Pharma we are deeply concerned about the war situation in Ukraine, hoping for a fast, peaceful resolution as soon as possible. Our thoughts are with everyone affected by this war and with the people who are suffering and fearing for their lives and livelihood. From the beginning, we are in continuous contact with […]
mAbxience launches its CDMO platform to third parties
02/28/2022
mAbxience, an experienced, specialized global biotechnology company, aims to leverage its capacity, expertise and proven track record in the optimization of biologic development & manufacturing programs for third parties. With a global mission to make biologic medicines accessible and affordable across the globe, mAbxience aims to focus its core expertise to accelerate and transform current […]
mAbxience’s biosimilar approved in Japan
02/23/2022
Nichi-Iko Pharmaceutical Co., Ltd. has recently announced that it received approval for a biosimilar of bevacizumab BS intravenous infusion 100 mg/400 mg, whose marketing authorization application was filed based on the clinical pharmacokinetic (PK) study data conducted in Japan in addition to the global Phase 3 study data conducted by mAbxience. Bevacizumab BS is highly […]
PAHO selects centers in Argentina, Brazil to develop COVID-19 mRNA vaccines
10/25/2021
Washington DC, September 21, 2021 (PAHO) – The Pan American Health Organization (PAHO) has announced the selection of two centers in Argentina and Brazil as regional hubs for the development and production of mRNA-based vaccines in Latin America in a bid to tackle COVID-19 and future infectious-disease challenges. The Bio-Manguinhos Institute of Technology on Immunobiologicals […]
European Commission Approves mAbxience’s Bevacizumab For The Treatment Of Certain Types Of Cancer
03/31/2021
The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe.
Spain’s mAbxience boosting biologics capacity with 4,000 L SUB
03/25/2021
Biosimilar maker and CDMO mAbxience will install an ABEC 4,000 L CSR bioreactor at its site in León, Spain. mAbxience, the biologics division of Spain’s Insud Pharma group, claims its León plant is “the biggest biologic plant in Spain and the first in Europe with fully integrated single-use technology in most processes.” Now the site […]